comparative effectiveness
The biomarker p-tau 217 best correlated with other established signs of Alzheimer's disease in a head-to-head study evaluating six blood-based assays.
The Institute for Clinical and Economic Review is seeking public comment on its plan to evaluate the cost-effectiveness of EGFR inhibitors and immunotherapies.